No Blood Thinners for You

The IRA Maximum Fair Price implementation created a system conflict inside UnitedHealthcare. Let’s talk about it.

A 71-year-old man with nonvalvular atrial fibrillation has been on Eliquis 5 mg twice daily for more than three years. No bleeding events, no adverse reactions, no therapy interruptions. His cardiologist has documented him as clinically stable at every follow-up. CHA₂DS₂-VASc score of 4, HAS-BLED score of 2. The drug is working. The patient is stable. There is nothing clinical to discuss.

Early in 2026 he tried to fill his prescription and left the pharmacy without his medication. His prior authorization was active, and his cardiologist had done everything correctly. The problem wasn’t clinical, and it wasn’t administrative. It was inside UnitedHealthcare’s own systems.

What happened

Prior authorization for continued Eliquis maintenance was obtained through UnitedHealthcare’s Part D utilization management portal. The portal evaluated the patient’s atrial fibrillation diagnosis, treatment history, stroke risk and bleeding risk, and returned a clean approval. Authorization active. No flags. No conditions.

The prescription went electronically to a retail pharmacy through the standard NCPDP claim pathway. UnitedHealthcare’s real-time pharmacy benefit system intercepted it at the PBM and returned a step therapy rejection. The rejection said the patient must show documented therapeutic failure on the preferred formulary alternative before the brand could be dispensed, and it added one sentence that should have triggered an immediate internal review: prior authorization approval does not override formulary placement restrictions effective January 1, 2026.

Read that twice. Their own clinical UM system approved the drug. Their own financial system blocked it. On the same day, for the same patient. Both are UnitedHealthcare systems, and they reached different conclusions.

Why it happened on January 1

Eliquis became subject to the Inflation Reduction Act’s Maximum Fair Price negotiated ceiling on January 1, 2026. In response, UnitedHealthcare restructured its Medicare Advantage Part D formulary placement for the drug, moving Eliquis from preferred brand to non-preferred brand with mandatory step therapy through a preferred alternative.

The step therapy gate was added to the pharmacy benefit’s financial configuration table on January 1. The clinical UM portal was not updated at the same time. The clinical system kept approving Eliquis under the old formulary classification while the financial system blocked it under the new one. Two internal systems, one drug, one patient, running different rule sets at the same time.

What the appeals produced

The first-level appeal submitted more than three years of stable therapy documentation, the CHA₂DS₂-VASc and HAS-BLED scores, and a letter from the cardiologist stating that switching anticoagulants in a stable elderly patient with controlled atrial fibrillation introduces unnecessary stroke and bleeding risk with no clinical benefit.

The uphold rationale contained the sentence that matters more than anything else in the file: “Prior authorization approval does not override formulary placement restrictions.” The payer acknowledged in writing that the clinical approval exists and is valid, then stated that the financial restriction overrides it.

The second-level appeal added cardiology society guidelines recommending against switching stable anticoagulation for non-clinical reasons, and CMS guidance on continuity of care for patients on stable maintenance therapy. It was upheld, with a recommendation to move to the preferred alternative or submit documented therapeutic failure.

Think about what that means clinically. In a 71-year-old with atrial fibrillation, therapeutic failure on an anticoagulant means a stroke, a major bleed or a significant adverse reaction. The step therapy protocol requires a documented adverse clinical outcome as a precondition for covering a drug that is currently preventing adverse clinical outcomes.

The patient

He left the pharmacy without medication. Three days later he called his cardiologist’s office to say he still couldn’t fill the prescription. The practice documented a five-day therapy gap before an emergency exception authorization was obtained, and the cardiologist documented the interruption as clinically inappropriate and potentially dangerous given his stroke risk.

Five days, because UnitedHealthcare’s financial configuration table and its clinical UM portal were running different criteria for the same drug and the same patient, and nobody inside caught it before the prescription reached the pharmacy.

This is not one patient’s problem

The Maximum Fair Price implementation affected Eliquis formulary placement across Medicare Advantage Part D plans nationally on January 1, 2026. Every plan that restructured formulary tiers without updating its clinical UM criteria at the same time is generating this same contradiction. Eliquis is one of the most prescribed drugs in the United States, and the population of Medicare Advantage Part D patients on stable Eliquis maintenance is enormous.

The practices seeing this pattern don’t see a system conflict. They see a formulary access issue, a step therapy denial, or a patient who couldn’t afford the medication. The underlying cause is two internal payer systems running different criteria on the same drug, and it is invisible unless someone reads the complete correspondence record and finds where the clinical approval and the financial block contradict each other.

What BMS and Pfizer can’t see

Bristol Myers Squibb and Pfizer’s data shows this as a step therapy rejection. Their field teams see a formulary access issue. Their hub reports show the prior authorization was approved. None of their data shows that their own drug’s clinical authorization is being overridden by a financial configuration change the clinical system doesn’t know about.

The patient who left the pharmacy without medication appears in their data as a dropped script, and the cause appears as cost-related non-adherence. The actual cause is a system conflict inside the payer. The correspondence file contains it. The 835 does not.

The contradiction that reverses this denial

UnitedHealthcare’s clinical UM portal approved Eliquis for this patient. UnitedHealthcare’s uphold letter acknowledged that approval is valid, then stated the financial restriction overrides it. Two UnitedHealthcare documents: one says approved, one says blocked. The authorization is the payer’s own record that this patient meets the clinical criteria. The block is a formulary change applied to one internal system and not the other.

Reversing it means presenting what the payer already wrote and showing where it says the opposite about the same patient and the same drug.

What to look for

If you prescribe Eliquis to Medicare Advantage Part D patients, pull claim activity for apixaban from January 2026 forward. Filter for step therapy rejections on patients with active prior authorizations. If a patient has an active authorization and a step therapy block on the same drug on the same date, the contradiction is documented in the payer’s own correspondence. The clinical approval and the financial block cannot coexist. That is the argument.

The timely filing window on January 2026 claims is running. On most Medicare Advantage contracts it is 365 days from the date of service. The clock is moving.